Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.47 |
| ▸ | C1R | P00736 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | TACR3 | P29371 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1758144 | 0.80 | ADORA2A (0.55) | ADORA2AMBNL1C1RTGFBR1MAPT | |
| SCHEMBL2126776 | 0.77 | ADORA2A (0.55) | ADORA2AMBNL1C1RMAPTGBA1 | |
| SCHEMBL17363620 | 0.76 | MBNL1 (0.61) | ADORA2AMBNL1C1RTGFBR1MAPT | |
| SCHEMBL13063652 | 0.75 | ADORA2A (0.57) | ADORA2AMBNL1C1RMAPTGBA1 | |
| SCHEMBL6335549 | 0.71 | ADORA2A (0.66) | ADORA2AMBNL1C1RTGFBR1MAPT | |
| SCHEMBL3772243 | 0.71 | ADORA2A (0.66) | ADORA2AMBNL1C1RTGFBR1MAPT | |
| SCHEMBL30462943 | 0.71 | MBNL1 (0.66) | ADORA2AMBNL1C1RTGFBR1MAPT | |
| SCHEMBL1757960 | 0.71 | KDM1A (0.46) | ADORA2ATGFBR1MAPTPOLBMAPK1 | |
| SCHEMBL2123544 | 0.71 | ADORA2A (0.53) | ADORA2AMBNL1C1RMAPTTACR3 | |
| SCHEMBL2123690 | 0.71 | ADORA2A (0.53) | ADORA2AMBNL1C1RTACR3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633718-B1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s | MILLENNIUM PHARM INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-1633718-B1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s | MILLENNIUM PHARM INC (US) | 2012-06-06 | — | — | EP | disclosed |
| US-7943640-B2 | 3-Fluoro-2-(2-methylsulfanyl-phenyl)-quinolin-4-yl]-pyridin-4-yl-amine; modulating transforming growth factor (TGF) - beta; fibroproliferative diseases or diseases associated with fibrosis; cardiovascular, urogenital and gastrointestinal disorders; antihypotensive, -arthritic agents; angioplasty | MILLENIUM PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943640-B2 | 3-Fluoro-2-(2-methylsulfanyl-phenyl)-quinolin-4-yl]-pyridin-4-yl-amine; modulating transforming growth factor (TGF) - beta; fibroproliferative diseases or diseases associated with fibrosis; cardiovascular, urogenital and gastrointestinal disorders; antihypotensive, -arthritic agents; angioplasty | MILLENIUM PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943640-B2 | 3-Fluoro-2-(2-methylsulfanyl-phenyl)-quinolin-4-yl]-pyridin-4-yl-amine; modulating transforming growth factor (TGF) - beta; fibroproliferative diseases or diseases associated with fibrosis; cardiovascular, urogenital and gastrointestinal disorders; antihypotensive, -arthritic agents; angioplasty | MILLENIUM PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-1633718-A4 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s | MILLENNIUM PHARM INC (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-7314939-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314939-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314939-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| EP-1633718-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050032835-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2004112710-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | TGFBR1, TGFB1, TGFBR2 | ADORA2A 795/4885MBNL1 2299/4885C1R 876/4885 |
| US-20050032835-A1 | Compositions and methods for inhibiting TGF-beta | TGFBR1, TGFB1, TGFBR2 | ADORA2A 795/4885MBNL1 2299/4885C1R 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.